Previous studies suggested that ctDNA testing has potential for real-time monitoring of tumor burden in patients with metastatic disease, with ctDNA mutations associated with targeted therapy response in patients with HER2-positive BC, and endocrine therapy response in patients with ER-positive metastatic BC [4,31,32]. Here, ESR1 is linked to neoplasm.